Infective endocarditis (IE) is a disease that affects multiple systems and results from infection, usually bacterial, of the endocardial surface of the heart. It has been recognized as a pathological entity for hundreds of years and as an infectious process since the nineteenth century 1 . In his landmark 1885 Gulstonian Lectures on malignant endocarditis, Sir William Osler presented a unifying theory in which susceptible patients developed 'mycotic' growths on their valves followed by "transference to distant parts of microorganisms" (REF. 2). The intervening 130 years have witnessed dramatic growth in our understanding of IE as well as fundamental changes in the disease itself. Medical progress, novel at-risk populations and the emergence of antimicrobial resistance have led to new clinical manifestations of IE. In this Primer, we review our current understanding of IE epidemiology, pathophysiology, aspects of diagnosis and clinical care, and speculate on future developments in IE and its management.
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Epidemiology IE is a relatively rare but life-threatening disease. In a systematic review of the global burden of IE, crude incidence ranged from 1.5 to 11.6 cases per 100,000 personyears, with high-quality data available from only ten -mostly high-income -countries 3 . Untreated, mortality from IE is uniform. Even with the best-available therapy, contemporary mortality rates from IE are approximately 25% 4 .
Demography
The mean age of patients with IE has increased considerably in the past several decades. For example, the median age of patients with IE presenting to Johns Hopkins Hospital was <30 years in 1926 (REF. 5 ). By contrast, more than half of contemporary patients with IE are >50 years of age, and approximately two-thirds of cases occur in men 4, 6 . Multiple factors have contributed to this changing age distribution in high-income countries. First, the cardiac risk factors that predispose patients to IE have shifted in many high-income countries from rheumatic heart disease, which is primarily seen in young adults, to degenerative valvular disease, which is principally encountered in the elderly. Second, the age of the population has increased steadily. Third, the relatively new entity of health care-associated IE, which disproportionately affects older adults, has emerged secondary to the introduction of new therapeutic modalities, such as intravascular catheters, hyperalimentation lines, cardiac devices and dialysis shunts.
past two decades 4 . However, in developing countries, rheumatic heart disease remains the most common predisposing cardiac condition for IE 8 . Prosthetic valves and cardiac devices (such as permanent pacemakers and cardioverter defibrillators) are significant risk factors for IE. Rates of implantation of these devices have increased dramatically in the past several decades. Consequently, prosthetic valves and cardiac devices are involved in a growing proportion of IE cases 9 . For example, in a recent cohort of 2,781 adults in 25 countries with definite IE, one-fifth had a prosthetic valve and 7% had a cardiac device 4 . Congenital heart disease also confers increased risk of IE. In the same study mentioned above 4 , 12% of the 2,781 patients with definite IE had underlying congenital heart disease. However, because this cohort was assembled largely from referral centres with cardiac surgery programmes, this rate probably overestimates the association between congenital heart disease and IE in the general population. Mitral valve prolapse has been reported as the predominant predisposing structural abnormality in 7-30% of native-valve IE (NVIE) in developing countries 10 . In one case-control study, mitral prolapse was associated with IE with an odds ratio of 8.2 (95% CI: 2.4-28.4) 11 . In developed countries, degenerative cardiac lesions assume greatest importance in the 30-40% of patients with IE who do not have known valvular disease 12 . For example, in an autopsy series, mitral valve annular calcification was noted in 14% of patients with IE who were >65 years of age, which is a higher rate than that of the general population 12, 13 . Other factors that predispose to IE include injection drug use (IDU), human immunodeficiency virus infection and extensive health care system contact 4, 6 . Health care-associated IE in particular has been rising in the past several decades, especially in developed countries 6 . For example, one-third of a recent prospective, multinational cohort of 1,622 patients with NVIE and no history of IDU had health care-associated IE 14 .
Microbiology
As patient risk factors change, the microbiology of IE also shifts. Although streptococci and staphylococci have collectively accounted for approximately 80% of IE cases, the proportion of these two organisms varies by region (FIG. 1) and has changed over time. The emergence of health care-associated IE has been accompanied by an increase in the prevalence of Staphylococcus aureus 15 and coagulase-negative staphylococci 14, 16 , whereas the proportion of IE due to viridans group streptococci (VGS) has declined 16 . Enterococci are the third leading cause of IE and are increasingly linked to health care contact 17 . Infections that involve Gram-negative and fungal pathogens in IE are rare and are primarily health care-associated when they do occur 18, 19 . In approximately 10% of cases of IE, blood cultures are negative, most commonly due to patient receipt of antibiotics before the diagnostic work-up. 'True' culturenegative IE is caused by fastidious microorganisms that are difficult to isolate with conventional microbiological techniques. Highly specialized assays, such as serological testing and PCR using blood or valve biopsies, can ultimately suggest a causative pathogen in up to 60% of such cases 20 . Although the aetiology of true culturenegative IE varies with geographical and epidemiological factors, important causes include Coxiella burnetii (the causative agent of Q fever), Bartonella spp., Brucella spp. and Tropheryma whipplei 4, 20 . Specific risk factors, such as contact with livestock or abattoirs (for Brucella spp. and Coxiella burnetii), homelessness or alcoholism (for Bartonella quintana), travel to the Middle East or the Mediterranean or consumption of unpasteurized dairy products (for Brucella spp.), contact with cats (for Bartonella henselae) or extensive health care contact in a patient with a prosthetic valve and negative blood cultures (for Aspergillus spp.) may be useful clues when evaluating potential IE cases.
Mechanisms/pathophysiology
Experimentally, the normal valvular endothelium is resistant to bacterial colonization upon intravascular challenge 21 . Thus, the development of IE requires the simultaneous occurrence of several independent factors: alteration of the cardiac valve surface to produce a suitable site for bacterial attachment and colonization; bacteraemia with an organism that is capable of attaching to and colonizing valve tissue; and creation of the infected mass or 'vegetation' by 'burying' of the proliferating organism within a protective matrix of serum molecules (for example, fibrin) and platelets (FIG. 2) .
bacteria show bacterial adhesion to the NBTE surface within 24 hours following infection. This adhesion is followed by the generation of the fully developed infected vegetation upon further coverage of the bacteria with matrix molecules 23 .
Transient bacteraemia
Bloodstream infection is a prerequisite for the development of NVIE and probably the bulk of prosthetic-valve IE (PVIE) cases; in the latter setting, intraoperative contamination could account for valve infection. However, the minimum magnitude of bacteraemia (as measured by colony-forming units (CFU) per ml) required to cause IE is not known. Experimental models have typically used inocula of 10 5 -10 8 CFU per ml either as a bolus dose or by continuous infusion over an extended period 24 . Lowgrade bacteraemia (≥10 and <10 4 CFU per ml) seems to be common after mild mucosal trauma, such as with dental, gastrointestinal, urological or gynaecological procedures 25 . Bacteraemia is readily detectable in a majority of patients after dental procedures 26 and after common daily activities, such as teeth brushing and chewing 25 . It is thus likely that low levels of bacteraemia, while commonplace, are usually insufficient to cause IE. In addition, many of the bacterial species present in the blood after mild mucosal trauma are not commonly implicated in cases of IE. For example, complement-mediated bactericidal activity eliminates most Gram-negative pathogens 27 . By contrast, organisms that are traditionally associated with IE (that is, S. aureus, Staphylococcus epidermidis, VGS, enterococci and Pseudomonas aeruginosa) adhere more readily to canine aortic leaflets in vitro than do pathogens that are less common causes of IE 28 . Even within the same species, there may be differences in the propensity to cause IE. Specific clonal complexes of S. aureus, for example, are associated with an increased risk of IE 29 . Similarly, members of the Streptococcus mitis-oralis group predominate as a cause of IE among the many members of VGS 30 .
Microorganism-NBTE interaction
Once bacteraemia has been established with a typical IE-inducing pathogen, the next step is adherence of the organism to the fibrin-platelet matrices of NBTE. The importance of this step was demonstrated in a study of dental extraction in rats with periodontitis. In this study, group G streptococci were responsible for 83% of IE episodes despite causing a minority of episodes of bacteraemia. In an in vitro model, these organisms were associated with increased adhesion to fibrin-platelet matrices compared with other species 31 . Adhesion to NBTE is also an important step in fungal IE. Whereas Candida krusei adheres poorly and is a rare cause of IE in humans, Candida albicans adheres to NBTE in vitro, readily produces experimental IE 32 and is the most common cause of IE among candidal species 19 .
Mechanisms of bacterial adherence to the endocardium. Although binding of the pathogen to NBTE seems to be a common step in establishing IE, the mechanism by which this occurs may vary considerably. Some organisms seem to bind to components of damaged endothelium or NBTE, such as fibronectin, laminin and collagen 33, 34 . Other organisms may bind directly to, or be internalized by, endothelial cells. This seems to be an important mechanism by which S. aureus infects cardiac valves 35, 36 (FIG. 3) . In this model, adhesion is mediated by S. aureus-specific surface proteins that bind to fibrinogen, such as clumping factor (Clf) and coagulase 37, 38 . It seems that a 'cooperativity' exists between the binding of fibrinogen and fibronectin in the induction of S. aureus IE, in which both adhesins mediate the initial attachment to vegetations, but fibronectin binding is crucial for the persistence of organisms at the valvular endothelial site 39 . Additional virulence factors, such as α-toxin, then mediate persistence and proliferation within maturing vegetations 40 . In addition, it seems that a key factor in adherence of oral streptococci to NBTE is dextran, which is a complex bacterial-derived extracellular polysaccharide 41, 42 . Other proposed virulence factors that mediate streptococcal adhesion include FimA, which is a surface protein that functions as an adhesin in the oral cavity 43, 44 , the sialic acid-binding adhesin Hsa 45 and a phage-encoded bac terial adhesin that mediates a complex interaction between bacteria, fibrinogen and platelets [46] [47] [48] .
Platelet aggregation and evolution of the vegetation.
Following bacterial colonization of the valve, the vegetation enlarges by further cycles of fibrin-platelet deposition and bacterial proliferation (FIG. 2) . Some strains of bacteria are potent stimulators of platelet aggregation and the platelet release reaction (that is, degranulation) 49 . In general, IE-producing strains of staphylococci and streptococci more actively aggregate platelets than do other bacteria that less frequently produce IE. Streptococcus sanguinis promotes platelet aggregation via two bacterial cell surface antigens 50 . S. aureus seems to be able to bind to platelets via platelet-derived von Willebrand factor or directly to the von Willebrand factor receptor 51, 52 . Although platelets are key components in the pathogenesis of IE, they also have a pivotal role in host defence against organism proliferation within the cardiac vegetation. For example, platelets phagocytose circulating staphylococci into engulfment vacuoles that fuse with α-granules. These α-granules contain antimicrobial peptides called platelet microbicidal proteins (PMPs). Depending on the intrinsic susceptibility of the specific strain of staphylococci to these bactericidal peptides, the organism is either killed within platelets or survives and disseminates using a 'Trojan Horse' mechanism 53 . Platelets also thwart bacterial proliferation within the vegetation by releasing antibacterial PMPs into the local vegetation environment 54 . Thus, resistance to PMPs (such as in S. aureus) contributes to virulence in IE. Finally, bacteria buried deep within the vegetation may exhibit a state of reduced metabolic activity based on an inability to uptake crucial nutrients 55 . This altered metabolic state promotes organism survival against selected antibiotics.
The invading microorganism, the endothelium and the monocyte interact in a complex manner in the pathogenesis of IE. After internalization by endothelial cells in vitro, microorganisms such as S. aureus evoke a potent pro-inflammatory chemokine response, including increased expression of IL-6, IL-8 and monocyte chemotactic peptide 56 . Monocytes are drawn into the endothelial cell microenvironment, where circulating bacteria may then bind directly to their surface, inducing the release of tissue thromboplastin (tissue factor) 57 . This release amplifies the procoagulant cascade that leads to the progressive evolution of the vegetation. As noted above, this same cascade also induces the antibacterial effect of PMP release by platelets within the vegetation matrix. 58, 59 . Of interest, clini cally persistent MRSA bacteraemia strains produce significantly more biofilm in vitro when exposed to sub inhibitory concentrations of vancomycin than do clinically resolving MRSA isolates 58 . Quorum sensing. As IE vegetations contain large densities of organisms, the role of quorum sensing genetic regulation (that is, the regulation of gene expression on the basis of bacterial cell density) of virulence factors has been raised. Most data in this regard emanate from S. aureus, in this case, in the context of the quor um sensing regulon agr (accessory gene regulator). Of interest, in experimental IE, the ability of MRSA strains to evoke activation of agr early in the growth cycle correlates with the ability to cause vancomycin-persistent IE both clinically and in experimental IE. However, based on agr gene knockout studies, the 'early activation' profile of agr is, at most, a biomarker for persistent IE strains rather than being directly linked to this outcome pathogenetically 58, 60 .
Immunopathological factors
IE results in stimulation of both humoral and cellular immunity, as manifested by hypergammaglobulinaemia, splenomegaly and the presence of macrophages in the peripheral blood. Several classes of circulating anti bodies are produced in response to the continuous bacter aemia that typically characterizes IE. Opsonic antibodies, agglutinating antibodies, complementfixing antibodies, cryo globulins and antibodies directed against bacterial heat shock proteins and macroglobulins are produced by the host in an effort to control the ongoing infection 61, 62 .
Effectiveness of antibody responses in IE.
Animal studies suggest variable effectiveness of the antibody response to prevent IE. For example, rabbits immunized with heatkilled S. sanguinis plus Freud's adjuvant had a higher ID 50 (that is, the S. sanguinis dose required to produce an infection in 50% of rabbits) than non-immunized controls after aortic valve trauma 63 . Antibodies against cell surface components reduce adhesion of C. albicans to fibrin and platelets in vitro and reduce the incidence of IE in vivo 64 . By contrast, whole-cell-induced anti bodies to S. epidermidis and S. aureus did not prevent IE in immunized animals 65 . In addition, when administered in conjunction with antibiotic therapy, antibodies speci fic for the fibrinogen-binding protein ClfA increased bacterial clearance from vegetations 66 . Moreover, recent data indicate a possible role for vaccination against ClfA for the prevention of IE 67 , although human studies have not yielded an effective vaccine (see Outlook section).
Pathological antibodies. Rheumatoid factor (which is an anti-IgG IgM antibody) develops in about half of patients with IE of >6 weeks duration 68 and decreases with antimicrobial therapy 69 . Although rheumatoid factor might contribute to pathogenesis by blocking IgG opsonizing activity, stimulating phagocytosis or accelerating microvascular damage, it does not seem to significantly contribute to immune complex glomerulo nephritis associated with IE 70 . Antinuclear antibodies also occur in IE and may contribute to the musculoskeletal manifestations, fever or pleuritic pain some of the peripheral manifestations of IE, such as Osler's nodes (a skin manifestation of IE) and Roth spots (retinal haemorrhages). Pathologically, these lesions resemble an acute Arthus reaction, in which antigenantibody complexes are deposited and lead to local vasculitis, although the finding of positive culture aspirates from Osler's nodes in one series suggests that these may be septic embolic phenomena 73 . Effective treatment leads to a prompt decrease in circulating immune complexes 74 , whereas therapeutic failures are characterized by rising titres of circulating immune complexes 75 .
Fastidious bacteria
Some organisms, such as the obligate intracellular patho gens C. burnetii and Bartonella spp., may cause IE by different pathophysiological mechanisms than those outlined above. In the case of C. burnetii, patients show a lack of macrophage activation, promoting intracellular survival of the organism and leading to the histopathological findings of empty or foamy macrophages that are suggestive of IE associated with Q fever 76 . Specific antibodies are produced, leading to immune complex formation. Affected valves exhibit sub endothelial infection with smooth, nodular vegetations that micro scopically demonstrate a mixture of fibrin deposits, necrosis and fibrosis without granulomas 77 .
Organ-specific pathology
As a systemic disease, IE results in characteristic pathological changes in multiple target organs 78 (FIG. 4) .
Portions of the fibrin-platelet matrix of the vegetation may dislodge from the infected heart valve and travel with arterial blood until lodging in a vascular bed downstream from the heart. Such septic emboli can involve almost any organ system in the body and can manifest clinically in several ways. First, if the embolus is large enough to deprive adjacent tissue of oxygen where it lodges, infarction of the dependent tissues can result. This is the pathogenetic process for embolic strokes, myocardial infarctions and infarctions of the kidney, Nature Reviews | Disease Primers spleen, mesentery and skin. Second, bacteria embedded within the embolus can invade local tissues and create a visceral abscess. Last, extracardiac manifestations may also arise from immune complex deposition or from direct seeding of other tissues as a result of bacteraemia.
Cardiac manifestations. In the heart, the classic vegetation is usually in the line of closure of a valve leaflet on the atrial surface of atrioventricular valves (the mitral and tricuspid valves) or on the ventricular surface of semilunar valves (the aortic and pulmonary valves). Vegetations vary in size and can reach several centimetres in diameter. The infection may lead to perforation of a valve leaflet or rupture of the chordae tendineae, interventricular septum or papillary muscle.
Valve ring abscesses with fistula formation in the myocardium or pericardial sac may result, especially with S. aureus. Finally, myocardial infarctions may occur as an embolic complication of IE, particularly in patients with aortic-valve IE 79 .
Renal manifestations.
In patients with IE, the kidney may develop infarction due to emboli, abscess due to direct seeding by an embolus or an immune complex glomerulonephritis. Renal biopsies performed during active IE are uniformly abnormal, even in the absence of clinically overt renal disease 80 .
Neurovascular manifestations.
Mycotic aneurysms are localized enlargements of arteries caused by infection of the artery wall and may be a feature of acute IE or may be detected months to years after successful treatment 81 . These aneurysms can arise via one of several mechanisms: direct bacterial invasion of the arterial wall with subsequent abscess formation; embolic occlusion of the vasa vasorum (which are small vessels that supply the walls of larger vessels); or immune complex deposition with resultant injury to the arterial wall 81 . Mycotic aneurysms tend to arise at bifurcation points, most commonly in the cerebral vessels, although almost any vascular bed can be affected. Cerebral aneurysms may be symptomatic, particularly if bleeding complications arise, but they may also be discovered in patients without neurological symptoms. For example, in one prospective series, 10 out of 130 consecutive patients with IE who underwent screening by cerebral MRI with angiography (a technique called magnetic resonance angiography) had clinically silent cerebral aneurysms 82 . Approximately 80% of all patients interrogated with magnetic resonance angio graphy in this study 82 showed asymptomatic 'microbleeds' in small peripheral cerebral vessels; whether these microbleeds predict future risk of symptomatic intracerebral haemorrhage is unknown 83 . Neurological manifestations of IE most frequently arise from cerebral emboli. These are clinically apparent in approximately 20-30% of patients with IE. However, if MRI of asymptomatic patients with IE is routinely undertaken, a majority will have evidence of cerebrovascular complications 82, 84 . The incidence of stroke in IE is 4.82 cases per 1,000 patient-days in the first week of IE and drops rapidly after starting antibiotics 85 . Splenic manifestations. Splenic infarcts are frequently found during autopsy of patients who died as a result of IE 86 but may also be clinically occult. Splenic abscesses tend to be clinically apparent, with pain, fever and leukocytosis. Splenomegaly is found in about 10% of patients with IE in the developed world 4 and is more common in patients with chronic IE (such as that caused by Q fever or VGS) than in acute cases, possibly as a consequence of prolonged immunological response.
Pulmonary manifestations. Thromboembolic showering -in which 'showers' of tiny emboli lodge within and occlude small vessels -can lead to the formation of septic pulmonary emboli, either with or without infarction. This phenomenon is a common complication of tricuspid-valve IE or other sources of microemboli, such as central venous catheters, that are located immediately 'upstream' of the lungs. Pneumonia, pleural effusions or empyema often accompany septic pulmonary emboli. Although septic pulmonary emboli most commonly appear as peripheral wedge-shaped densities on chest radiographs, rounded 'cannonball' lesions that mimic tumours may sometimes develop 87 .
Skin manifestations. Skin findings in IE include petechiae, cutaneous infarcts, Osler's nodes and Janeway lesions. At the microscopic level, Osler's nodes consist of arteriolar intimal proliferation with extension to venules and capillaries and may be accompanied by thrombosis and necrosis. A diffuse perivascular infiltrate composed of neutrophils and monocytes surrounds the dermal vessels. Immune complexes may be found within the lesions. Janeway lesions are caused by septic emboli and are characterized by the presence of bacteria, neutrophils, necrosis and subcutaneous haemorrhage 88 .
Ocular manifestations.
Patients with IE may have Roth spots in their eyes. These immunological phenomena appear on funduscopic examination as retinal haemorrhages with a pale centre (FIG. 4) . Microscopically, they consist of fibrin-platelet plugs or lymphocytes surrounded by oedema and haemorrhage in the nerve fibre layer of the retina 89 . In addition, direct bacteraemic seeding of the eye may occur, causing endophthalmitis (that is, inflammation of the lining of the intraocular cavities) involving the vitreous and/or aqueous humours 90 . Endophthalmitis is especially prevalent with S. aureus IE. For instance, in a prospective cohort of patients with S. aureus bacteraemia, 10 out of 23 (43%) patients who had IE also had ocular infection 91 .
Diagnosis, screening and prevention

Diagnosis
The diagnosis of IE typically requires a combination of clinical, microbiological and echocardiography results. Historically, and as is probably still the case in resource-limited settings, IE was diagnosed clinically based on classic findings of active valvulitis (such as cardiac murmur), embolic manifestations and immunological vascular phenomena in conjunction with positive blood cultures. These manifestations were the hallmarks of subacute or chronic infections, most often in young patients with rheumatic heart disease. However, in the modern era in developed countries, IE is usually an acute disease with few of these hallmarks because the epidemiology has shifted towards health care-associated IE, often with early presentations due to S. aureus. In this context, fever is the most common presenting symptom but is nonspecific 4 . The presence of other risk factors, such as IDU or the presence of intravascular prosthetic material, should increase the clinical suspicion for IE in a febrile patient. This clinical variability complicates efforts to identify patients with IE who would benefit from early effective antibiotics or cardiac valve surgery. The ability to reliably exclude IE is also important, both to avoid extended courses of unnecessary antibiotics and to focus diagnostic considerations onto other possibilities.
Diagnostic techniques.
Blood culture is the most important initial laboratory test in the work-up of IE. Bacteraemia is usually continuous 92 and the majority of patients with IE have positive blood cultures 4 . If antibiotic therapy has been administered before the collection of blood cultures, the rate of positive cultures declines 93 . Modern blood culture techniques now enable isolation of most pathogens that cause IE. For this reason, practices that were traditionally used to facilitate isolation of fastidious pathogens, such as the use of specific blood culture bottles or extending incubation beyond 5 days, are no longer generally recommended 94 .
In cases of suspected IE when cultures are negative 95 , other microbiological testing approaches may be useful (TABLE 1) . For example, serological testing is necessary for the diagnosis of Q fever, murine typhus 96 and psittacosis 97 . In addition, Bartonella spp. can be isolated with special culture techniques 98 and serological studies may also be helpful for identifying this pathogen. Culture of valvular tissue may yield a causative organism when blood cultures are negative, and microscopy for fastidious or intracellular pathogens may also be diagnostic 76, 99 . Molecular techniques to recover specific DNA or 16S ribosomal RNA from valve tissue 100 and blood or serum samples 20 have been helpful in selected cases. Other investigative techniques have been reported (TABLE 1) , although they are not widely available.
Echocardiography is the second cornerstone of diagnostic efforts and should be performed in all patients in whom IE is suspected 101, 102 . Transthoracic echocardiography (TTE) may enable visualization of vegetations in many patients (FIG. 5) . The sensitivity of TTE is variable 103 and is highest in right-sided IE owing to the proximity of the tricuspid and pulmonic valves to the chest wall. Transoesophageal echocardiography (TOE) is more sensitive than TTE for the detection of vegetations and other intracardiac manifestations of IE, especially in the setting of prosthetic valves 104 . Thus, TTE and TOE are complementary imaging modalities. Both the 2015 European Society of Cardiology (ESC) and the 2015 American Heart Association (AHA) guidelines advocate echocardiography for all cases of suspected IE and encourage TOE for cases in which (FIG. 5) . The use of multimodality imaging is likely to increase in the future if additive benefits can be demonstrated, and the 2015 ESC guidelines have incorporated these modalities into the diagnostic algorithm of PVIE 102 . Diagnostic criteria. The original 114 and subsequently modified Duke criteria 115 provide the current goldstandard diagnostic strategy, which is both sensitive and specific for IE. The original Duke criteria were evaluated in multiple studies [116] [117] [118] [119] [120] from geographically and clinically diverse populations, confirming their high sensitivity and specificity.
The modified Duke criteria stratify patients with suspected IE into three categories -'definite' , 'possible' and 'rejected' IE -on the basis of major and/or minor criteria
. Microbiological criteria form the first major criterion, with diagnostic weight accorded to bacteraemia with pathogens that typically cause IE. For organisms with a weaker association with IE, persistently positive blood cultures are required. The second major criterion is evidence of endocardial involvement, as demonstrated by echocardiography or findings of new valvular regurgitation. Minor criteria include a predisposing heart condition or IDU, fever, vascular phenomena, immunological phenomena or microbiological evidence that does not meet a major criterion.
Thus, IE diagnosis cannot be made on the basis of a single symptom, sign or diagnostic test. Rather, the diagnosis requires clinical suspicion, most commonly triggered by systemic illness in a patient with risk factors, followed by evaluation according to the diagnostic schema outlined in the modified Duke criteria. It is worth keeping in mind that the Duke criteria were originally developed to facilitate epidemiological and clinical research efforts and that the application of the criteria to the clinical practice setting is more difficult. The heterogeneity of patient presentations necessitates clinical judgement in addition to application of the criteria. Moreover, the criteria may be further modified as evidence accrues for new microbiological and imaging modalities. The 2015 ESC diagnostic algorithm has incorporated additional multimodal imaging (such as cardiac CT, PET-CT or leukocyte-labelled single-photon emission CT) for the challenging situation of 'possible' or 'rejected' PVIE by modified Duke criteria but with a persisting high level of suspicion for IE 102 . The substantial morbidity and mortality of IE has inspired efforts to prevent its occurrence in at-risk individuals. These prevention efforts have historically focused on oral health because VGS are normal oral flora and cause approximately 20% of IE cases 16 . Based on the assumption that dental procedures may lead to IE in patients with underlying cardiac disease, the AHA and other major society guidelines previously recommended prophylactic antibiotic therapy to prevent IE in patients with underlying cardiac conditions who underwent dental procedures 121 . More recently, however, this recommendation has come into question. There is now substantial evidence that transient bacteraemia is common with normal daily activities, including tooth brushing, flossing and chewing food, and the efficacy of antimicrobial prophylaxis is unknown 25 . In a departure from previous guidance, the 2002 French IE prophylaxis guidelines were the first to dramatically reduce dental prophylaxis indications 122 . The 2007 AHA guidelines reduced the recommended scope of cardiac conditions for which dental prophylaxis is reasonable to four clinical settings: patients with prosthetic valves or valve material; patients who had previous IE; patients with a subset of congenital heart disease; and cardiac transplant ation recipients who develop cardiac valvulopathy 121 . Prophylaxis is no longer recommended for gastro intestinal or genitourinary procedures. Guidelines from the ESC similarly recommended using dental prophy laxis only for those with highest risk of developing IE 102 . Recommendations of the UK National Institute for Health and Clinical Excellence (NICE) were published in 2008 and were even more restrictive, advising against IE prophylaxis for any dental, gastrointestinal, genitourinary or respiratory tract procedures 123 . Subsequent to the 2008 NICE guidelines, there was a highly significant 78.6% reduction in prescribing of antibiotic prophylaxis before dental procedures in the United Kingdom. With 2 years of follow-up data after guideline publication, there did not seem to be an appreciable increase in IE cases or deaths 124 . Similarly re assuring data were reported following the introduction of the revised French and AHA guidelines 16, 125 . However, poor adherence to the AHA guidelines complicates interpretation of these results in the United States 126 . Recently, increasing concerns have accompanied the availability of longer durations of follow-up. After extending the follow-up period in England through 2013, the number of IE cases seemed to increase significantly over the projected historical trend, leading to an estimated additional 35 more cases per month than would have been expected if prior prophylaxis rates had continued 127 . The increase was seen in patients in all risk categories as defined in the AHA and the ESC guidelines. However, this study did not contain organism-specific data, so it was not possible to tell whether this increase was due to VGS -which might plausibly have been prevented by dental prophylaxis -or to other pathogens, such as S. aureus. Subsequently, in the United States, a retrospective review of 457,052 IE-related hospitalizations in the Nationwide Inpatient Sample database suggested a similar trend, with an increase in IE hospitalization rates, both overall and due to organisms categorized as 'streptococcal' , after the release of the new guidelines 128 . However, it was noted that enterococci were included in the streptococcal category and that the apparent increase in streptococcal IE might thus be owing to rising enterococcal IE rates 129 .
To date, at least nine population-based studies have examined IE rates before and after guideline changes (TABLE 2) . Taken together, these data indicate that there may be both efficacy and risk (in the form of antibioticrelated adverse events) associated with antibiotic prophylaxis. Importantly, all of the available evidence derives from observational cohorts, with imprecise microbiological data. Furthermore, even if IE rates did increase following guideline changes, a causal relationship cannot be established. No prospective randomized controlled studies to assess the efficacy of prophylaxis have been performed, despite calls for such a trial for at least the past 25 years 130 . In a 2015 review of the prior 2008 guidelines, the NICE elected not to change any of the prior recommendations and reiterated the need for a randomized controlled trial comparing prophylaxis with no prophylaxis, including long-term follow-up for incident IE 131 . In addition to dental prophylaxis, efforts at prevention of intravascular catheter-related bacteraemia may also reduce the incidence of health care-associated IE. Bacteraemia rates are reduced by quality improvement interventions, such as care bundles or checklists that consist of strict hand hygiene, use of full-barrier precautions during the insertion of central catheters, cleaning the skin with chlorhexidine, avoiding the femoral site if possible and removing unnecessary catheters 132 . Confirmatory data on the effect of these interventions on IE incidence are not available.
Management
In the modern era, management of IE typically requires a multidisciplinary team, including, at a minimum, an infectious disease specialist, a cardiologist and a cardiac surgeon 133 . All patients should receive antimicrobial therapy and a subset may benefit from cardiovascular surgical intervention.
General principles of antimicrobial therapy
The primary purpose of antimicrobial therapy is to eradicate infection. Several characteristics of infected vegetations pose particular challenges in this regard 55 , including high bacterial density (also called the 'inoculum effect') 134 , slow rates of bacterial growth in biofilms and low microorganism metabolic activity 135 . As a result, extended courses of parenteral therapy with bactericidal (or fungicidal) agents are typically required.
Duration of therapy.
The duration of therapy must be sufficient to completely eradicate microorganisms within cardiac vegetations. Owing to poor penetration of antibiotics into these vegetations and the slowly bactericidal properties of some of the commonly used drugs (such as vancomycin), extended courses of antibiotics are usually required. When bactericidal activity is rapid, shorter courses may be feasible. For example, combination therapy with penicillin or ceftriaxone and an aminoglycoside is synergistic for VGS-associated IE, enabling effective courses as short as 2 weeks for susceptible strains 101 . Right-sided vegetations tend to have lower bacterial densities than left-sided vegetations and may also be amenable to shorter course therapy.
The duration of antimicrobial therapy is generally calculated from the first day on which blood cultures are negative. Blood cultures should be obtained every 24-72 hours until it is demonstrated that the bloodstream infection has cleared 101, 102 . If operative valve tissue cultures are positive, an entire antimicrobial course should be considered following cardiovascular surgery. Considerations for prosthetic valves and implantable cardiac devices. For NVIE, treatment duration ranges from 2 weeks to 6 weeks, whereas a treatment dur ation of 6 weeks is usually used for PVIE. The antibiotics used for NVIE and PVIE are typically the same, with the exception of staphylococcal PVIE, for which the addition of rifampin and gentamicin is recommended.
Infections of cardiac implantable electronic devices (such as pacemakers and defibrillators) may occur with or without associated valvular IE 137 . Regardless of whether infection seems to involve the device lead alone (which is sometimes termed 'lead endocarditis'), the valve alone, or both, complete device and lead removal is recommended 138 . There are limited clinical data to inform the optimal duration of antibiotic therapy for cardiac device infections; at least 4-6 weeks, using the same antibiotics as for valvular IE, are recommended for lead endocarditis 138 .
Organism-specific considerations
Staphylococci. The crucial distinction in selecting antibiotic therapy for S. aureus-associated IE is whether the isolate is methicillin-resistant (MRSA) or methicillinsusceptible (MSSA). Anti-staphylococcal β-lactam antibiotics are recommended whenever possible for MSSA-associated IE, as data from observational studies indicate worse outcomes for patients with MSSA bloodstream infections who are treated with vancomycin 105, 139 . Whether it is necessary to use a β-lactam antibiotic as empirical therapy is unclear; small retrospective studies have suggested a potential benefit 140 . A more recent cohort study among >5,000 patients with MSSA bacterae mia suggested that β-lactams are superior for definitive therapy once MSSA has been identified, but not for empirical treatment 139 . Providers might avoid prescribing β-lactams to patients with reported penicillin allergies. However, among patients with a reported penicillin allergy, most do not have a true allergy when skin testing is performed 141 , and skin testing seemed to be cost-effective in decision analyses for treating MSSA bactaeremia 142 and IE
143
. For MRSA IE, vancomycin has historically been the antibiotic of choice and it remains a first-line therapy in treatment guidelines 101, 102, 136, 144 . Recent reports have raised the concern that after decades of use, the vancomycin minimum inhibitory concentration (MIC) for S. aureus might be rising 145 . Increased vancomycin MICs, even among isolates still classified as susceptible, might be associated with worse outcomes in MRSA bacter aemia, although meta-analyses have reached different conclusions 146, 147 . In a prospective cohort of 93 patients with left-sided MSSA IE who were treated with cloxa cillin, high vancomycin MIC (≥1.5 mg per l) was associated with increased mortality, even though these patients did not receive vancomycin 148 . In light of this finding, it seems that a higher vancomycin MIC may be a surrogate marker for host-specific or pathogenspecific factors that lead to worse outcomes. Clinicians may consider the use of an alternative antibiotic for MRSA IE with a vanco mycin MIC of ≥1.5 mg per l, but data are lacking to support a mortality benefit for alternative approaches. Ultimately, the clinical response of the patient should determine the continued use of vancomycin, independent of the MIC 144 . Daptomycin is approved by the US FDA for the treatment of adults with S. aureus bactaeraemia and rightsided IE and is an alternative to vancomycin for MRSA IE 101 . The FDA-approved dose for IE is 6 mg per kg per day, but many authorities use higher doses (such as 8-10 mg per kg per day) owing to concerns for treatmentemergent resistance, which occurred in approximately 5% of patients (7 out of 120 daptomycin-treated patients) in the phase III trial comparing dapto mycin to standard therapy for S. aureus bacteraemia and IE 149 . Daptomycin seems to be safe and effective at these higher doses [150] [151] [152] .
Gentamicin is not recommended for staphyl ococcal NVIE 101 because it is associated with nephrotoxicity and does not have robust data to support clinical benefit 153 . Similarly, rifampin is also not recommended as an adjunct therapy for NVIE 101 because it has been associated with adverse effects 154 and prolonged bacteraemia 155 and should be avoided in staphylococcal NVIE unless there is another indication for its use, such as concurrent osteoarticular infection. For staphylococcal PVIE, weak evidence supports the use of both gentamicin and rifampin 156 . A large trial examining the role of adjunctive rifampin for S. aureus bacteraemia has recently completed enrolment 157 . Observational data have been reported for other antibiotic combinations. For example, ceftaroline is a cephalosporin antibiotic active against MRSA and has been used as salvage therapy for IE alone or in combination with other anti-staphylococcal antibiotics 158, 159 . Other combinations have shown in vitro synergy and have limited human data in MRSA bacteraemia, such as vancomycin or daptomycin paired with β-lactams or with trimethoprim-sulfamethoxazole, daptomycin plus fosfomycin, or fosfomycin combined with β-lactams 160, 161 . Recommended treatment regimens for coagulase-negative staphylococci are the same as those for S. aureus 101, 102 .
Streptococci. Standard treatment for streptococcal IE is a β-lactam antibiotic (such as penicillin, amoxicillin or ceftriax one) for 4 weeks. The addition of an aminoglycoside may enable a shorter 2-week course of therapy when administered once daily in combination with ceftriax one for streptococcal NVIE 101, 162 . For streptococcal isolates with an increased penicillin or ceftriaxone MIC, gentamicin should be added 101 .
Enterococci. From the early days of the antibiotic era, clinicians noted that penicillin worked less well for enterococci than for streptococci and combination therapy with an aminoglycoside was therefore recommended 163 . Although this has remained the standard approach, increasing rates of aminoglycoside resistance and the toxicity associated with this class of antibiotics have spurred efforts to find alternative therapeutic options.
Recent data indicate that the combination of ampicillin and ceftriaxone may be effective for IE due to ampicillin-susceptible Enterococcus faecalis, particularly in patients with aminoglycoside resistance, or in whom there is concern for nephrotoxicity with an aminoglycoside 164, 165 . Vancomycin-resistant enterococcal IE is fortunately rare but has been successfully treated with linezolid 166 and daptomycin 152 . If daptomycin is used, high-dose therapy may be considered 101 .
Other organisms. HACEK group organisms (Haemo philus spp., Aggregatibacter spp., Cardio bacterium hominis, Eikenella corrodens and Kingella spp.) were historically treated with ampicillin. However, β-lactamase-producing strains are increasingly problematic and susceptibility testing may fail to identify these strains 167 . Thus, HACEK organisms should be considered ampicillin-resistant and ceftriaxone is the preferred treatment. A duration of 4 weeks of therapy is generally sufficient for these organisms 101 . IE due to non-HACEK Gram-negative bacilli is rare 18 . Consequently, optimal management strategies are not defined. Cardiac surgery combined with prolonged antibiotic therapy is considered a reasonable strategy in many cases 101 . Fungal IE is also rare but outcomes are poor. Valve sur gery is often used, but this approach is not clearly associ ated with improved outcomes 168 . Following initial paren teral therapy with an amphotericin-based regimen or an echinocandin, indefinite azole therapy is recommended, particularly if valve surgery is not performed 169, 170 .
Culture-negative IE. Culture-negative IE cases are particu larly challenging to manage. Although sterile blood cultures are most commonly due to patient receipt of antibiotics before obtaining blood cultures, they may also arise from inadequate micro biological techniques, infection with fastidious organisms or non-infectious causes of valvular vegetations, such as marantic or Libman-Sacks IE. Choosing an antibiotic regimen in these cases requires balancing the need for empirical therapy for all the likely pathogens with the potential adverse effects of using multiple anti biotics. Investigation for 'true' culture-negative IE (that is, for uncommon pathogens that do not grow in routine blood cultures) may yield an aetiology in these cases.
Surgery
The rate of early valve replacement or repair has increased over time 4 in keeping with the prevailing opinion that surgery is a key component of the management of many complicated IE cases. However, the evidence base for this practice is decidedly mixed. A single randomized trial demonstrated a significant reduction in the composite outcome of in-hospital deaths and embolic events with early surgery 171 . While clearly transformational, study generalizability was nonetheless questioned. Study subjects were younger, healthier and infected with less-virulent pathogens (for example, VGS) than contemporary patients with IE encountered in general practice 172 . For most patients with IE, recommendations for surgery are based on observational studies and expert opinion.
The principal consensus indications for valve surgery are heart failure, uncontrolled infection and prevention of embolic events in patients at high risk of IE. Uncontrolled infection may be related to paravalvular complications, such as abscess, an enlarging vegetation or dehiscence of a prosthetic valve. In addition, uncontrolled infection may be manifested by ongoing systemic illness with persistent fevers and positive blood cultures despite appropriate antibiotic therapy. As larger left-sided vegetations are more likely to lead to embolic events, IE with a vegetation of >10 mm in length is a relative indication for surgical intervention.
The timing of cardiac surgery for patients with IE and neurovascular complications remains controversial.
A large prospective cohort study of 857 patients with IE complicated by ischaemic stroke without haemorrhagic conversion found that no patient benefit was gained from delaying surgery 173 . By contrast, patients with embolic stroke complicated by haemorrhagic conversion sustained higher mortality when surgery was performed within 4 weeks of the haemorrhagic event than with later surgery (75% versus 40%, respectively) 174 . On the basis of these observational data, the AHA currently recommends that valve surgery may be considered in patients with IE who also have stroke or subclinical cerebral emboli without delay if intracranial haemorrhage has been excluded by imaging studies and neurological damage is not severe (such as coma). In patients with major ischaemic stroke or intracranial haemorrhage, AHA guidelines currently state that delaying valve surgery for at least 4 weeks is reasonable 101 . Valve surgery was traditionally recommended for difficult-to-treat pathogens, such as Pseudomonas aeruginosa, fungal organisms and β-lactam-resistant staphylococci. However, these pathogen-specific recommendations for surgery have been recently called into question in favour of an individualized decisionmaking approach based on haemodynamic and structural indications 168, 175 .
Other adjunctive therapies Anticoagulation. Patients with PVIE who are receiving oral anticoagulants may be at an increased risk of death from cerebral haemorrhage 176 . Antiplatelet therapies are not currently recommended for IE. A single randomized trial examined the role of 325 mg of aspirin daily for patients with IE. The incidence of embolic events was similar between aspirin-treated and placebo-treated patients, and there was a non-significant increase in the rate of cerebral bleeding episodes 177 . However, there are several limitations to this study, including the dose of aspirin used and the delayed initiation of aspirin. For patients with another indication for antiplatelet therapy, it may be reasonable to continue the antiplatelet agent unless bleeding complications develop. Similarly, it is not recommended to initiate anticoagulant therapy such as warfarin for the purpose of treating IE. In patients with IE who have another indication for antico agulation therapy, such as a mechanical valve, data are contradictory on whether to continue anticoagulation during acute therapy 176, 178 , and bridging therapy with heparin products has not been studied.
Management of metastatic foci.
Metastatic foci of infection frequently complicate IE. As with any infection, recog nition of these foci of infection is important so that targeted interventions, such as drainage of abscesses or removal of infected prosthetic material, may be undertaken. This is of crucial importance in patients who require valve surgery because a persistent source of infection may serve as a source from which a recently placed prosthetic valve or annuloplasty ring becomes infected 101, 102 . Some metastatic foci, such as vertebral osteomyelitis, may require additional anti biotic therapy beyond what is typically indicated for IE 179 . There is currently insufficient evidence to recommend specific imaging strategies to look for metastatic foci in all patients with IE.
Care at completion of therapy
Most patients with IE in the modern era are cured and attention can eventually turn to a follow-up plan. Elements of follow-up may include an echocardiogram at the completion of antimicrobial therapy to establish a new baseline for subsequent comparison, referral to a drug cessation programme for patients with IDUs and a thorough dental evaluation. A comprehensive search for the initial portal of pathogen entry may be undertaken so that this can be addressed to minimize repeat episodes of IE. In a prospective single-centre experience, a systematic search revealed the likely source in 74% of 318 patients 180 . Routine blood cultures at completion of antibiotic therapy are not recommended given a very low rate of positivity in patients with no signs of active infection. Patients should also be monitored for complications of IE, including relapse, incident heart failure and complications of antibiotic therapy, such as audiological toxicity from aminoglycosides or incident Clostridium difficile infection.
Quality of life
In addition to the stress associated with being diagnosed with a potentially lethal infection, patients with IE routinely experience prolonged hospitalizations and adverse reactions to treatment, and undergo multiple invasive procedures. For instance, treatment for left-sided IE requires extended courses of intravenous antibiotics, which involves long-term venous access and probably diminishes patient quality of life (QOL).
To what extent these factors may impair the QOL of patients after they are discharged from the hospital is not well known, as only a few studies have addressed these issues [181] [182] [183] . In addition, life-threatening illness may cause post-traumatic stress disorder (PTSD), which has been shown to impair patient well-being in survivors of various life-threatening infectious diseases.
In one study of QOL in survivors of left-sided NVIE, 55 out of 86 eligible adults completed questionnaires 3 and 12 months after discharge from hospital and 12 more patients completed the 12-month questionnaires only. The health-related QOL was measured using the 36-Item Short-Form Health Survey and the PTSD questionnaires. In this study, 41 out of 55 patients (75%) and 36 out of 67 patients (54%) still had physical symptoms 3 and 12 months after the end of antimicrobial treatment, respectively. The most prevalent symptoms were weakness of the limbs (51%), fatigue (47%) and concentration disorders (35%). One year after discharge, 7 out of 64 patients (11%) were still suffering from PTSD. The 37 patients who were ≤60 years of age at the time of IE were questioned about their employment status. Before IE, 30 (81%) patients were employed and working. At 3 and 12 months, 16 out of 31 patients (52%) and 24 out of 37 patients (65%) were working again, respectively 182 . Given the low number of patients evaluated, the effect of factors, such as causative microorganisms or valve surgery, on QOL and on the rate of PTSD could not be assessed. In one study conducted in patients without IE who had undergone mitral valve surgery, the type of surgery (replacement versus repair) had no effect on the QOL of patients 184 .
Whether a comprehensive cardiac rehabilitation programme (which typically involves exercise and information sessions) may improve the QOL of patients surviving IE is currently being explored through a randomized clinical trial (the CopenHeart IE study) 185 , in which 150 patients treated for left-sided (NVIE or PVIE) or cardiac device IE will be randomized to either cardiac rehabilitation or usual care 186 .
In a qualitative evaluation of 11 patients recovering from IE, Rasmussen et al. 187 described the innovative concept of 'insufficient living' . Some patients described an 'altered life' period as a phase of adaptation to a new life situation, which some perceived as manageable and temporary, whereas others found it to be extremely distressing and prolonged. Patients also described a 'shocking weakness' feeling that was experienced physically, cognitively and emotionally. These feelings subsided quickly for a few, whereas most patients experienced a persisting weakness and felt frustrated about the prolonged recovery phase. Finally, patients expressed that support from relatives and health care professionals, as well as one's own actions, were important in facilitating recovery. This original study emphasized the need for research in follow-up care to support a patient's ability to cope with potential physical and psychoemotional consequences of IE 187 . Given the scarcity of data on the subject, future studies are needed to define the effect of IE on patient QOL. Potential priorities for future research in IE QOL are listed in BOX 2.
Outlook Treatment Future treatments for IE will emphasize pragmatism. For example, an effective treatment strategy for left-sided IE that avoids long-term venous access would be an important advance. At least two randomized trials are testing the effectiveness and safety of replacing part of the standard intravenous antibiotic course with a 'step-down' strategy to oral antibiotics 188, 189 . In addition, two newly approved anti-staphylococcal antibiotics -dalbavancin and oritavancin -might eventually repre sent alternatives to the current standard intravenous treatment strategies for IE. Along these lines, the POET study uses a noninferiority, multicentre, prospective, randomized, openlabel study design to test the hypothesis that partial oral antibiotic treatment is as safe and effective as parenteral therapy in left-sided IE 188 . A total of 400 stable patients with streptococcal, staphylococcal or entero coccal aortic or mitral valve IE will be ran domized to receive a full 4-6 weeks of intravenous antibiotics or to receive oral antibiotics after a minimum of 10 days of parenteral therapy. Patients will be followed up for 6 months after completion of antibiotic therapy. The primary end point is a composite of all-cause mortality, unplanned cardiac surgery, embolic events and relapse of positive blood cultures with the primary pathogen. A non-inferiority margin of 10% is proposed.
The RODEO study, using the same primary end point, will also evaluate the impact of switching to oral therapy for left-sided IE 189 . In this study, 324 subjects with IE due to MSSA will receive at least 10 days of intravenous antibiotic therapy, then will be randomized to complete a full 4-6 weeks of intravenous therapy or to receive oral levofloxacin and rifampin for at least 14 additional days.
Dalbavancin and oritavancin, which are lipoglycopeptide-class antibiotics that were approved in 2014 by the FDA for the treatment of acute bacterial skin and skin structure infections (ABSSSIs), represent potential improvements to the current options of intravenous therapy for IE. An important property is their extremely long half-life, estimated to be 10-14 days 190, 191 , which allows infrequent administration. Dalbavancin is approved by the FDA for the treatment of ABSSSIs using a single 1,500 mg dose or with a two-dose strategy: a 1,000 mg loading dose on day 1 followed by a 500 mg infusion 1 week later 192, 193 . Oritavancin is approved for the treatment of ABSSSIs as a single 3-hour infusion of 1,200 mg 194 . These dosing strategies might ultimately avoid the need for home health or skilled nursing facility care for outpatient intravenous antibiotics. Although no data are currently available for the efficacy of such treatment strategies in IE, the pharmacokinetics of dalbavancin dosed at 1,000 mg of dalbavancin on day 1 followed by 500 mg weekly for 7 additional weeks seemed to be favourable in one phase I study 190 . In addition, dalbavancin was studied in catheter-associated bloodstream infection 195 . Therapies not requiring extended intra venous access, such as dalbavancin or oritavancin, could be especially advantageous in treating IE in patients with IDU or who have limited options for intravascular line placement.
Vaccines to prevent common bacterial causes of IE
The best way to treat IE is to prevent it. Although most efforts to date on IE prevention have focused on infection control and dental prophylaxis, considerable resources have also been invested in vaccine development that targets common bacterial causes of IE. Success has been mixed and none of these agents is currently commercially available. Nonetheless, future prevention strat egies for some causes of IE are likely to include vaccines. Although vaccine candidates for pathogens such as VGS 196 and C. albicans 197 . All three trials focus on specific adult populations at high risk for S. aureus infection, including those undergoing haemodialysis (in the StaphVAX vaccine trial), cardiac surgery (in the V710 vaccine trial) and spinal surgery (the SA4Ag vaccine trial).
StaphVAX (Nabi Biopharmaceuticals, Rockville, Maryland, USA) is a bivalent vaccine of capsular polysaccharides 5 and 8 that was tested in 1,804 patients with a primary fistula or synthetic graft vascular access undergoing haemodialysis. Although receipt of StaphVAX was associated with a significant reduction in rates of S. aureus bacteraemia at 40 weeks post-vaccination (efficacy: 57%; P = 0.02), the study failed to demonstrate significantly reduced rates of S. aureus bacteraemia at the prespecified end point of 54 weeks post-vaccination 200 . Thus, a second trial of StaphVAX in 3,600 patients undergoing haemodialysis was undertaken. In this second study, the primary efficacy end point was set at 6 months. Unfortunately, this unpublished trial also failed to demonstrate protection against the development of S. aureus bacteraemia. V710 is a vaccine that targets the cell wall constitutive iron-regulatory protein IsdB and was tested in patients undergoing median sternotomy. The study was terminated after approximately 8,000 patients were enrolled owing to lack of efficacy and also to a higher rate of multiple organ system failure-related deaths among patients who received V710. In post-hoc analyses, patients that received V710 and subsequently became infected with S. aureus were approximately five-times more likely to die than patients that received control and then became infected with S. aureus (23 versus 4.2 per 100 person-years) 221 . The reason for this increased mortality is unknown.
A phase IIb study of the SA4Ag vaccine has been initiated. This study aims to test the efficacy and safety of a vaccine that targets S. aureus infection in patients who are undergoing elective posterior instrumented lumbar spinal fusion surgery 199 . Unlike previous S. aureus vaccine approaches, this candidate vaccine includes four epitopes: ClfA, manganese transport protein C (MntC) and capsular polysaccharides 5 and 8.
At least two other S. aureus vaccine candidates are in late preclinical development. Candidate vaccine NDV-3 contains the amino-terminal portion of the C. albicans agglutinin-like sequence 3 protein (Als3p) formulated with an aluminium hydroxide adjuvant. Preclinical studies have demonstrated that the Als3p vaccine antigen protects mice from mucocutaneous and intravenous challenge with both C. albicans 197 and S. aureus 201 . The vaccine has been shown to be safe and immunogenic in healthy adults 202 . Most recently, a multi-subunit vaccine that targets five known S. aureus virulence determinants -α-haemolysin (Hla), ess extracellular A (EsxA), EsxB, and the surface proteins ferric hydroxamate uptake D2 and conserved staphylococcal antigen 1A -was described. When formulated with a novel Tolllike receptor 7-dependent agonist, the five antigens provided high levels of T helper 1-driven protection against S. aureus in animal models 203 .
Conclusions
Although much has changed since Osler elucidated its fundamental disease mechanisms in the late 1800s, IE remains a disease of high morbidity and mortality with far-reaching effects on the QOL of survivors. In the near term, the epidemiology will continue to reflect the epidemiological and microbiological effect of health care contact. Improved algorithms for the diagnosis of IE will incorporate new microbiological techniques, especially for blood culture-negative cases. We can safely assume that imaging technology will continue to advance, and further research is needed to define which patients with suspected IE should undergo TOE and which patients may benefit from newer imaging modalities. Novel Gram-positive antibiotics are promising but as yet untested in IE. If proven to be effective, they might enable simpler and more-patient-friendly treatment regimens. It is likely that the debate around IE prophylaxis will continue until prophylaxis strategies are compared prospectively. Vaccine development has not yet yielded an effective and commercially available product, but numerous candidates are in the pipeline.
